The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact on treatment effectiveness of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
 
Keito Suzuki
No Relationships to Disclose
 
Yutaka Yasui
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Eisai; Lilly Japan; Takeda
 
Kaoru Tsuchiya
Consulting or Advisory Role - Chugai Pharma; Eisai
Speakers' Bureau - Chugai Pharma; Eisai; Lilly Japan; Takeda
 
Hiroaki Matsumoto
No Relationships to Disclose
 
Yudai Yamazaki
No Relationships to Disclose
 
Naoki Uchihara
No Relationships to Disclose
 
Yuki Tanaka
No Relationships to Disclose
 
Haruka Miyamoto
No Relationships to Disclose
 
Michiko Yamada
No Relationships to Disclose
 
Taisei Keitoku
No Relationships to Disclose
 
Risa Okada
No Relationships to Disclose
 
Mayu Higuchi
No Relationships to Disclose
 
Kenta Takaura
No Relationships to Disclose
 
Shohei Tanaka
No Relationships to Disclose
 
Chiaki Maeyashiki
No Relationships to Disclose
 
Nobuharu Tamaki
No Relationships to Disclose
 
Hiroyuki Nakanishi
No Relationships to Disclose
 
Yuka Takahashi
No Relationships to Disclose
 
Masayuki Kurosaki
Consulting or Advisory Role - Chugai Pharma; Eisai
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Eisai; Lilly Japan; Takeda
 
Namiki Izumi
Consulting or Advisory Role - Chugai Pharma; Eisai
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Eisai; Lilly Japan; Takeda